Crossmark

Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial

Crossref DOI link: https://doi.org/10.1186/s12885-025-13552-y

Published Online: 2025-01-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kuncman, Łukasz

Fijuth, Jacek

Tworek, Damian

Sierko, Ewa

Cisek, Paweł

Masłowski, Michał

Lisik-Habib, Maja

Orzechowska, Magdalena

Galwas-Kliber, Katarzyna

Antczak, Adam

Chmielewska, Izabela

Ziółkowska, Barbara

Kurczewska-Michalak, Marta

Kuźnicki, Wojciech

Jędrzejczak, Nina

Ranoszek, Kinga

Bilski, Mateusz
Funding

Funding for this research was provided by:

Medical Research Agency (2023/ABM/01/00040)

Medical Research Agency (2023/ABM/01/00040)

Medical Research Agency (2023/ABM/01/00040)
License Information

Text and Data Mining valid from 2025-01-24

Version of Record valid from 2025-01-24
More Information

Article History

Received: 7 January 2025

Accepted: 17 January 2025

First Online: 24 January 2025

Declarations

:

: This research complies with the Helsinki Declaration and has been approved by Medical University of Lodz Ethics committee.Trial registration: Clinicaltrials.gov identifier: NCT06529081; Registered 26 July 2024. A signature of the informed consent will be obtained from all patients before inclusion in the study.

: Not applicable. No patient-level information in this manuscript.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below